Source: GlobeNewswire

Press Release: Dermira : Almirall and Dermira Enter into Option and License Agreement for European Rights to Lebrikizumab

- Almirall acquires option to license rights to develop and commercialize lebrikizumab for atopic dermatitis in Europe- Dermira to receive an option fee of $30 million- Lebrikizumab is an investigational anti-IL-13 monoclonal antibody currently in Phase 2b development with topline data expected by early April 2019

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Estimated Annual Revenue

Estimated Employees

Thomas G. Wiggans's photo - Chairman & CEO of Dermira

Chairman & CEO

Thomas G. Wiggans

CEO Approval Rating


Dermira develops and commercializes therapeutics for the treatment of dermatological diseases.

Dermira is a Private compa...
Read more